Abstract
The Rho family of Ras superfamily small GTPases regulates a broad range of biological processes such as migration, differentiation, cell growth and cell survival. Therefore, the availability of small molecule modulators as tool compounds could greatly enhance research on these proteins and their biological function. To this end, we designed a biochemical, high throughput screening assay with complementary follow-up assays to identify small molecule compounds inhibiting MgcRacGAP, a Rho family GTPase activating protein involved in cytokinesis and transcriptionally upregulated in many cancers. We first performed an in-house screen of 20,480 compounds, and later we tested the assay against 342,046 compounds from the NIH Molecular Libraries Small Molecule Repository. Primary screening hit rates were about 1% with the majority of those affecting the primary readout, an enzyme-coupled GDP detection assay. After orthogonal and counter screens, we identified two hits with high selectivity towards MgcRacGAP, compared with other RhoGAPs, and potencies in the low micromolar range. The most promising hit, termed MINC1, was then examined with cell-based testing where it was observed to induce an increased rate of cytokinetic failure and multinucleation in addition to other cell division defects, suggesting that it may act as an MgcRacGAP inhibitor also in cells.
Keywords: Biochemical assays, cytokinesis, HTS, MgcRacGAP, Rac1, small molecule inhibitor.
Combinatorial Chemistry & High Throughput Screening
Title:Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP
Volume: 18 Issue: 1
Author(s): Arjan J. van Adrichem, Annika Fagerholm, Laura Turunen, Anna Lehto, Jani Saarela, Ari Koskinen, Gretchen A. Repasky and Krister Wennerberg*
Affiliation:
- Institute for Molecular Medicine Finland FIMM, Nordic EMBL Partnership for Molecular Medicine, Biomedicum Helsinki 2U, P.O. Box 20 (Tukholmankatu 8), FI- 00014, University of Helsinki, Finland.,Finland
Keywords: Biochemical assays, cytokinesis, HTS, MgcRacGAP, Rac1, small molecule inhibitor.
Abstract: The Rho family of Ras superfamily small GTPases regulates a broad range of biological processes such as migration, differentiation, cell growth and cell survival. Therefore, the availability of small molecule modulators as tool compounds could greatly enhance research on these proteins and their biological function. To this end, we designed a biochemical, high throughput screening assay with complementary follow-up assays to identify small molecule compounds inhibiting MgcRacGAP, a Rho family GTPase activating protein involved in cytokinesis and transcriptionally upregulated in many cancers. We first performed an in-house screen of 20,480 compounds, and later we tested the assay against 342,046 compounds from the NIH Molecular Libraries Small Molecule Repository. Primary screening hit rates were about 1% with the majority of those affecting the primary readout, an enzyme-coupled GDP detection assay. After orthogonal and counter screens, we identified two hits with high selectivity towards MgcRacGAP, compared with other RhoGAPs, and potencies in the low micromolar range. The most promising hit, termed MINC1, was then examined with cell-based testing where it was observed to induce an increased rate of cytokinetic failure and multinucleation in addition to other cell division defects, suggesting that it may act as an MgcRacGAP inhibitor also in cells.
Export Options
About this article
Cite this article as:
van Adrichem J. Arjan, Fagerholm Annika, Turunen Laura, Lehto Anna, Saarela Jani, Koskinen Ari, Repasky A. Gretchen and Wennerberg Krister*, Discovery of MINC1, a GTPase-Activating Protein Small Molecule Inhibitor, Targeting MgcRacGAP, Combinatorial Chemistry & High Throughput Screening 2015; 18 (1) . https://dx.doi.org/10.2174/1386207318666141205112730
DOI https://dx.doi.org/10.2174/1386207318666141205112730 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Thrombotic Microangiopathy and Occult Neoplasia
Cardiovascular & Hematological Disorders-Drug Targets Modification of Tumor Microenvironment Utilizing Nanotechnology Advancement for Better Therapeutic Effect
Nanoscience & Nanotechnology-Asia Flavaglines: Their Discovery from Plants Used in Traditional Chinese Medicine, Synthesis, and Drug Development Against Cancer and Immune Disorders
Current Chinese Chemistry Modulation of Sensitivity to Antitumor Agents by Targeting the MAPK Survival Pathway
Current Pharmaceutical Design Development and Applications of Optical Imaging Techniques in Cancer Diagnosis: Diffuse Optical Tomography and Microendoscopy
Current Medical Imaging Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Berberine Interfered with Breast Cancer Cells Metabolism, Balancing Energy Homeostasis
Anti-Cancer Agents in Medicinal Chemistry The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry The Analysis of the Druggable Families Based on Topological Features in the Protein-Protein Interaction Network
Letters in Drug Design & Discovery Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Ligand-Targeted Liposomes for Cancer Treatment
Current Drug Delivery Urtica dioica Extract Inhibits Cell Proliferation and Induces Apoptosis in HepG2 and HTC116 as Gastrointestinal Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry The Use of n-3 Polyunsaturated Fatty Acids as Therapeutic Agents for Inflammatory Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Exome-wide pharmacogenomic analysis of response to thiopurines in inflammatory bowel disease patients
Current Pharmacogenomics and Personalized Medicine Roles of Retinoic Acid in Induction of Immunity and Immune Tolerance
Endocrine, Metabolic & Immune Disorders - Drug Targets Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Understanding and Applying Personalized Therapeutics at Systems Level:Role for Translational Bioinformatics
Current Pharmacogenomics and Personalized Medicine Canonical and Non-Canonical Barriers Facing AntimiR Cancer Therapeutics
Current Medicinal Chemistry